Comment on Lipsky et al.: Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Por Tam, Constantine S., Kamel, Sarah
Publicado no Haematologica (2016)

Efficacy and Safety of Ruxolitinib in the Treatment of Patients with Myelofibrosis

Por Yi, Cecilia Arana, Tam, Constantine S., Verstovsek, Srdan
Publicado no Future Oncol (2015)

Splenectomy in patients with Myeloproliferative Neoplasms: efficacy, complications and impact on survival and transformation

Por Santos, Fabio P S, Tam, Constantine S, Kantarjian, Hagop, Cortes, Jorge, Thomas, Deborah, Pollock, Raphael, Verstovsek, Srdan
Publicado em 2013

Ibrutinib may impair serological responses to influenza vaccination

Por Douglas, Abby P., Trubiano, Jason A., Barr, Ian, Leung, Vivian, Slavin, Monica A., Tam, Constantine S.
Publicado no Haematologica (2017)

Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents

Por Cheson, Bruce D., Heitner Enschede, Sari, Cerri, Elisa, Desai, Monali, Potluri, Jalaja, Lamanna, Nicole, Tam, Constantine
Publicado no Oncologist (2017)

Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chron...

Por Tam, Constantine S., Kantarjian, Hagop, Garcia-Manero, Guillermo, Borthakur, Gautam, O'Brien, Susan, Ravandi, Farhad, Shan, Jenny, Cortes, Jorge
Publicado em 2008

Myelosuppression After Frontline Fludarabine, Cyclophosphamide, and Rituximab in Patients With Chronic Lymphocytic Leukemia: Analysis of Persistent and New-Onset Cytopenia

Por Strati, Paolo, Wierda, William, Burger, Jan, Ferrajoli, Alessandra, Tam, Constantine, Lerner, Susan, Keating, Michael J., O’Brien, Susan
Publicado no Cancer (2013)

p53 Expression by Immunohistochemistry is an Independent Determinant of Survival in Chronic Lymphocytic Leukemia Patients Receiving Frontline Chemo-Immunotherapy

Por Schlette, Ellen J, Admirand, Joan, Wierda, William, Abruzzo, Lynne, O'Brien, Susan, Lerner, Susan, Keating, Michael J, Tam, Constantine
Publicado no Leuk Lymphoma (2009)

Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Por Tam, Constantine S., Kantarjian, Hagop, Cortes, Jorge, Lynn, Alice, Pierce, Sherry, Zhou, Lingsha, Keating, Michael J., Thomas, Deborah A., Verstovsek, Srdan
Publicado no J Clin Oncol (2009)

Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia

Por Saulep-Easton, Damien, Vincent, Fabien B., Le Page, Melanie, Wei, Andrew, Ting, Stephen B., Croce, Carlo M., Tam, Constantine, Mackay, Fabienne
Publicado em 2014

The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells

Por Saulep-Easton, Damien, Vincent, Fabien B., Quah, Pin Shie, Wei, Andrew, Ting, Stephen B., Croce, Carlo M., Tam, Constantine, Mackay, Fabienne
Publicado no Leukemia (2015)

Chemoimmunotherapy May Overcome the Adverse Prognostic Significance of 11q Deletion in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Por Tsimberidou, Apostolia-Maria, Tam, Constantine, Abruzzo, Lynne V., O'Brien, Susan, Wierda, William G., Lerner, Susan, Kantarjian, Hagop M., Keating, Michael J.
Publicado no Cancer (2009)

Rituximab is associated with improved survival for aggressive B cell CNS lymphoma(†)

Por Gregory, Gareth, Arumugaswamy, Ashwini, Leung, Teresa, Chan, Kah-Lok, Abikhair, Melody, Tam, Constantine, Bajel, Ashish, Cher, Lawrence, Grigg, Andrew, Ritchie, David, Opat, Stephen
Publicado em 2013

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

Por Tam, Constantine S., O'Brien, Susan, Wierda, William, Kantarjian, Hagop, Wen, Sijin, Do, Kim-Anh, Thomas, Deborah A., Cortes, Jorge, Lerner, Susan, Keating, Michael J.
Publicado em 2008

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivit...

Por Jabbour, Elias, Jones, Daniel, Kantarjian, Hagop M., O'Brien, Susan, Tam, Constantine, Koller, Charles, Burger, Jan A., Borthakur, Gautam, Wierda, William G., Cortes, Jorge
Publicado em 2009

The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course

Por Tam, Constantine S., Abruzzo, Lynne V., Lin, Katherine I., Cortes, Jorge, Lynn, Alice, Keating, Michael J., Thomas, Deborah A., Pierce, Sherry, Kantarjian, Hagop, Verstovsek, Srdan
Publicado no Blood (2009)

Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression

Por Admirand, Joan H., Knoblock, Ronald J., Coombes, Kevin R., Tam, Constantine, Schlette, Ellen J., Keating, Michael J., Luthra, Rajyalakshmi, Medeiros, L. Jeffrey, Abruzzo, Lynne V.
Publicado em 2010

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

Por Tam, Constantine S., O’Brien, Susan, Plunkett, William, Wierda, William, Ferrajoli, Alessandra, Wang, Xuemei, Do, Kim-Anh, Cortes, Jorge, Khouri, Issa, Kantarjian, Hagop, Lerner, Susan, Keating, Michael J.
Publicado no Blood (2014)

Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor

Por Verstovsek, Srdan, Tam, Constantine S., Wadleigh, Martha, Sokol, Lubomir, Smith, Catherine C., Bui, Lynne A., Song, Chunyan, Clary, Douglas O., Olszynski, Patrycja, Cortes, Jorge, Kantarjian, Hagop, Shah, Neil P.
Publicado no Leuk Res (2013)

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

Por Thompson, Philip A., Tam, Constantine S., O’Brien, Susan M., Wierda, William G., Stingo, Francesco, Plunkett, William, Smith, Susan C., Kantarjian, Hagop M., Freireich, Emil J., Keating, Michael J.
Publicado no Blood (2016)